• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Apitope - Articles and news items

global-rights-multiple

Apitope regains global rights to its multiple sclerosis treatment from Merck

Industry news / 18 October 2016 / Niamh Louise Marriott, Digital Content Producer

In 2009, Apitope granted exclusive worldwide rights to Merck to develop and commercialise ATX-MS-1467 but now have successfully regained…

ATX-MS-1467

Enrolment completes for Phase IIa trial of ATX-MS-1467

Industry news / 6 August 2015 / Victoria White

Apitope today announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467 (also known as M2736)…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +